He said that royally-owned Siam Bioscience had been the most obvious choice of many companies considered for technology transfer from pharmaceutical firm AstraZeneca to make 200 million vaccine doses each year for Thailand and other nations.Siam Bioscience is wholly owned by a subsidiary of the Crown Property Bureau, which manages tens of billions of dollars in investments under the king’s personal control.
Thanathorn made his comments on Facebook Live on Monday at an event titled"Royal Vaccine: Who Benefits and Who Doesn't?" "We want to focus on our responsibility to produce the vaccine in time, with quality, with the appropriate amount," Songpon told Reuters.READ: Thai hospital ordered to stop advertising sale of COVID-19 vaccine
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: